Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug
Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with ...
Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...
manilatimes3d
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B ...
CBS News5d
Ozempic, Wegovy sales inject wealth into Novo Nordisk home country of Denmark
even their letter O sometimes comes slashed in half. But, Denmark is also home to what is suddenly Europe's largest company—Novo Nordisk…. a pharmaceutical firm with a market cap of a half ...
J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU)
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Novo Nordisk: Q3 Earnings Snapshot
The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 91 cents per share.
manilatimes2d
Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
Bagsværd, Denmark, 8 November 2024 - Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of ...
Fortune on MSN6d
Danish town where weight-loss wonder drug Ozempic is made suffers from the highest rates of overweight children in Denmark
A more tragic irony in the town is an obesity crisis among residents living in the shadow of the massive Wegovy-making plant.
Barclays Sticks to Their Buy Rating for Novo Nordisk (0QIU)
Barclays analyst Emily Field maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Forecasting The Future: 7 Analyst Projections For Novo Nordisk
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $159.43, a high estimate of $160.00 ...
Obesity Drug Maker Novo Nordisk Posts Strong Profit
Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by ...